From basic research to the bedside: Efficacy of topical treatment with pseudocatalase PC-KUS in 71 children with vitiligo

International Journal of Dermatology

Volumn 47, Issue 7, 2008, Pages 743-753

  Schallreuter, Karin U ^a   Krüger, Christian ^a,b   Würfel, Brigitte A ^a,b   Panske, Angela ^a,b   Wood, John M ^a,b  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; BETA CAROTENE; CALCIPOTRIOL; CATALASE; CYANOCOBALAMIN; FOLIC ACID; HYDROGEN PEROXIDE; KHELLIN; PHENYLALANINE; PIMECROLIMUS; PSEUDOCATALASE PC KUS; PSORALEN; STEROID; TACROLIMUS;

ADOLESCENT; ARTICLE; BASIC RESEARCH; BODY SURFACE; CHILD; CHILD CARE; CLIMATOTHERAPY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HOMEOPATHY; HUMAN; LENTIGO; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; ONSET AGE; PEDIATRICS; PHOTOGRAPHY; PROGNOSIS; RADIATION DOSE; RETROSPECTIVE STUDY; RISK REDUCTION; SIDE EFFECT; SKIN COLOR; SKIN PIGMENTATION; SUNBURN; SWEATING; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; VITILIGO;

ADMINISTRATION, TOPICAL; ADOLESCENT; AGE FACTORS; CATALASE; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PUVA THERAPY; RESEARCH; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEX FACTORS; TREATMENT OUTCOME; VITILIGO;

EID: 47649087692     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2008.03660.x     Document Type: Article

References (42)

1. Van den Wijngaard RM, Aten J, Scheepmaker A, et al. Expression and modulation of apoptosis regulatory molecules in human melanocytes: significance in vitiligo. Br J Dermatol 2000; 143: 573-581.
2. Tobin DJ, Swanson NN, Pittelkow MR, et al. Melanocytes are not absent in lesional skin of long duration vitiligo. J Pathol 2000; 191: 407-416.
3. Bhawan J, Bhutani LK. Keratinocyte damage in vitiligo. J Cutan Pathol 1983; 10: 207-212.
4. Moellmann G, Klein-Angerer S, Scollay DA, et al. Extracellular granular material and degeneration of keratinocytes in the normally pigmented epidermis of patients with vitiligo. J Invest Dermatol 1982; 79: 321-330.
5. Boissy RE, Manga P. On the etiology of contact/occupational vitiligo. Pigment Cell Res 2004; 17: 208-214.
6. 2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase. J Invest Dermatol Symp Proc 1999; 4: 91-96.
7. Medrano EE, Nordlund JJ. Successful culture of adult human melanocytes obtained from normal and vitiligo donors. J Invest Dermatol 1990; 95: 441-445.
8. Schallreuter KU, Wood JM, Lemke KR, et al. Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: A case study on 33 patients. Dermatology 1995; 190: 223-229.
9. Schallreuter KU. Successful treatment of oxidative stress in vitiligo. Skin Pharmacol Appl Skin Physiol 1999; 12: 132-138.
10. Schallreuter KU, Wood JM, Berger J. Low catalase levels in the epidermis of patients with vitiligo. J Invest Dermatol 1991; 97: 1081-1085.
11. Schallreuter KU Basic research: An update. In: Lotti T, Herzogova J, eds. Vitiligo. Problems and Solutions. New York: Marcel Decker, 2004: 65-78.
12. Aronoff S. Catalase: Kinetics of photooxidation. Science 1965; 150: 72-73.
13. Maresca V, Flori E, Briganti S, et al. UVA-induced modification of catalase charge properties in the epidermis is correlated with the skin phototype. J Invest Dermatol 2006; 126: 182-190.
14. Wood JM, Schallreuter KU. UVA-irradiated pheomelanin alters the structure of catalase and decreases its activity in human skin. J Invest Dermatol 2006; 126: 13-14.
15. 2): Potential and pitfalls. J Invest Dermatol 2006; 126: 2576-2582.
16. Schallreuter KU, Wood JM. Thioredoxin reductase in control of the pigmentary system. Clin Dermatol 1989; 7: 92-105.
17. Schallreuter KU, Wood JM. Thioredoxin reductase - its role in epidermal redox status. J Photochem Photobiol B 2001; 64: 179-184.
18. 2 stress. J Invest Dermatol 2004; 122: 307-313.
19. Schallreuter KU, Chiuchiarelli G, Cemeli E, et al. Estrogens can contribute to hydrogen peroxide generation and quinone-mediated DNA damage in peripheral blood lymphocytes from patients with vitiligo. J Invest Dermatol 2006; 126: 1036-1042.
20. Dell'Anna ML, Ottaviani M, Picardo M. Functional and structural index of cellular impairment during vitiligo. J Invest Dermatol 2006; 126(Suppl. 3): Abstract 403.
21. Spencer JD, Gibbons NC, Rokos H, et al. Oxidative stress via hydrogen peroxide affects proopiomelanocortin peptides directly in the epidermis of patients with vitiligo. J Invest Dermatol 2007; 127: 411-420.
22. Schallreuter KU, Wood JM, Pittelkow MR, et al. Increased monoamine oxidase A activity in the epidermis of patients with vitiligo. Arch Dermatol Res 1996; 288: 14-18.
23. Darr D, Fridovich I. Free radicals in cutaneous biology. J Invest Dermatol 1994; 102: 671-675.
24. Wong GH, Goeddel DV. Induction of manganous superoxide dismutase by tumor necrosis factor: Possible protective mechanism. Science 1988; 242: 941-944.
25. Moretti S, Spallanzani A, Amato L, et al. New insights into the pathogenesis of vitiligo: Imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res 2002; 15: 87-92.
26. Schallreuter KU, Moore J, Behrens-Williams S, et al. In vitro and in vivo identification of "pseudocatalase" activity in Dead Sea water using Fourier transform Raman spectroscopy. J Raman Spectrosc 2002; 33: 586-592.
27. Schallreuter KU, Wood JM, Pittelkow MR, et al. Regulation of melanin biosynthesis in the human epidermis by tetrahydrobiopterin. Science 1994; 263: 1444-1446.
28. Anderson D, Schmid TE, Baumgartner A, et al. Oestrogenic compounds and oxidative stress (in human sperm and lymphocytes in the Comet assay). Mutat Res 2003; 544: 173-178.
29. Schallreuter KU, Rokos H, Chavan B, et al. Quinones are reduced by 6-tetrahydrobiopterin in human keratinocytes, melanocytes and melanoma cells. Free Radic Biol Med 2008; 44: 538-546.
30. Shalbaf M, Gibbons NCJ, Wood JM, et al. Presence of epidermal allantoin further oxidative stress in vitiligo online DOI: 10.111/J 1600-625 2008 00697.x.
31. 2: More evidence for oxidative stress in vitiligo. Biochem Biophys Res Commun 2004; 315: 502-508.
32. Schallreuter KU. Vitiligo. In: Autoimmune Diseases of the Skin. Pathogenesis, Diagnosis, Management, 2nd edn. Wien: Springer, 2005, 367-384.
33. Völzke H, Lüdemann J, Robinson DM, et al. The prevalence of undiagnosed thyroid disorders in a previously iodine-deficient area. Thyroid 2003; 13: 803-810.
34. Aghini-Lombardi F, Antonangeli L, Martino E, et al. The spectrum of thyroid disorders in an iodine-deficient community: The Pescopagano survey. J Clin Endocrinol Metab 1999; 84: 561-566.
35. Schallreuter KU, Kothari S, Elwary S, et al. Molecular evidence that halo in Sutton's naevus is not vitiligo. Arch Dermatol Res 2003; 295: 223-228.
36. de Vijlder HC, Westerhof W, Schreuder GM, et al. Difference in pathogenesis between vitiligo vulgaris and halo nevi associated with vitiligo is supported by an HLA association study. Pigment Cell Res 2004; 17: 270-274.
37. Schallreuter KU, Elwary S. Hydrogen peroxide regulates the cholinergic signal in a concentration dependent manner. Life Sci 2007; 80: 2221-2226.
38. Elwary SM, Chavan B, Schallreuter KU. The vesicular acetylcholine transporter is present in melanocytes and keratinocytes in the human epidermis. J Invest Dermatol 2006; 126: 1879-1884.
39. Hill-Beuf A, Porter JD. Children coping with impaired appearance: Social and psychologic influences. Gen Hosp Psychiatry 1984; 6: 294-301.
40. Schallreuter KU. Damned White Spots: A Collection of Words and Images by Patients with Vitiligo. Bradford: University of Bradford, 1999: 112.
41. Schallreuter KU, Moore J, Behrens-Williams S, et al. Rapid initiation of repigmentation in vitiligo with Dead Sea climatotherapy in combination with pseudocatalase (PC-KUS). Int J Dermatol 2002; 41: 482-487.
42. Schallreuter KU. Effectiveness of pseudocatalase formulations in vitiligo. Clin Exp Dermatol 2003; 28: 562-563; author reply 563.